Diabetes: The Silent Epidemic | Golden Age

Diabetes, a chronic metabolic disorder affecting over 460 million people worldwide, is a pressing global health concern with significant economic and social implications. The disease is characterized by high blood sugar levels, which can lead to severe complications such as heart disease, kidney failure, and blindness if left untreated. According to the International Diabetes Federation, the global prevalence of diabetes is expected to reach 578 million by 2030, with type 2 diabetes accounting for approximately 90% of all cases. The rising incidence of diabetes is attributed to factors such as obesity, physical inactivity, and an unhealthy diet, highlighting the need for comprehensive prevention and management strategies. Researchers like Dr. Frederick Banting, who discovered insulin in 1921, have played a crucial role in shaping our understanding of the disease. As the global diabetes community continues to navigate the complexities of this epidemic, it is essential to address the controversy surrounding the role of pharmaceutical companies, such as Novo Nordisk and Eli Lilly, in shaping diabetes treatment and management.